Europe: Creating a digital hub for patients and caregivers

T2EVOLVE is a consortium working to accelerate the process of developing CAR T-cell therapy in the European Union (EU) to support patient access to this type of technology, while providing guidance on costs and implementation for EU healthcare systems.¹⁵²

As part of their program, the consortium is developing a central digital hub for patients and caregivers, co-created with leading European patient advocacy groups and clinicians involved in CAR T-cell therapy. This will build on their existing patient hub, containing patient information resources co-created with Working Group of Patients and Caregivers (WGPC), EuroGCT, Acute Leukemia Advocate Network (ALAN), Myeloma Patients Europe (MPE) and Lymphoma Coalition.¹⁵⁶ This additional platform aims to provide accessible, multilingual educational resources, practical guidance and support tools to empower patients and caregivers, thus enhancing patient’s understanding of their CAR T-cell therapy journey.¹⁵⁷